Rivastigmine

Rivastigmine
Clinical data
Trade names	Exelon, others
AHFS/Drugs.com	Monograph
MedlinePlus	a602009
License data	US DailyMed: Rivastigmine;
Pregnancy; category	AU: B2;
Routes of; administration	By mouth, transdermal patch
ATC code	N06DA03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	60 to 72%
Protein binding	40%
Metabolism	Liver, via pseudocholinesterase
Elimination half-life	1.5 hours
Excretion	97% in urine
Identifiers
	IUPAC name (S)-3-[1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate;
CAS Number	123441-03-2 ;
PubChem CID	77991;
IUPHAR/BPS	6602;
DrugBank	DB00989 ;
ChemSpider	70377 ;
UNII	PKI06M3IW0;
KEGG	D03822 ;
ChEBI	CHEBI:8874 ;
ChEMBL	ChEMBL636 ;
CompTox Dashboard (EPA)	DTXSID7023564 ;
ECHA InfoCard	100.120.679
Chemical and physical data
Formula	C14H22N2O2
Molar mass	250.342 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Oc1cc(ccc1)[C@@H](N(C)C)C)N(CC)C;
	InChI InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1 ; Key:XSVMFMHYUFZWBK-NSHDSACASA-N ;
	(what is this?) (verify)

Rivastigmine, sold under the brand name Exelon among others, is an acetylcholinesterase inhibitor used for the treatment of dementia associated with Alzheimer's disease and with Parkinson's disease. Rivastigmine can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.

Rivastigmine is eliminated through the urine, and appears to have relatively few drug-drug interactions.

It was patented in 1985 and came into medical use in 1997.